Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid

  1. Ke Peng
  2. Walter Muranyi
  3. Bärbel Glass
  4. Vibor Laketa
  5. Stephen R Yant
  6. Luong Tsai
  7. Tomas Cihlar
  8. Barbara Müller
  9. Hans-Georg Kräusslich  Is a corresponding author
  1. Heidelberg University, Germany
  2. German Center for Infection Research, Germany
  3. Gilead Sciences Inc., United States
  4. University Heidelberg, Germany

Abstract

The steps from HIV-1 cytoplasmic entry until integration of the reverse transcribed genome are currently enigmatic. They occur in ill-defined reverse-transcription- and pre-integration-complexes (RTC, PIC) with various host and viral proteins implicated. Here, we report quantitative detection of functional RTC/PIC by labeling nascent DNA combined with detection of viral integrase. We show that the viral capsid (CA) protein remains associated with cytoplasmic RTC/PIC, but is lost on nuclear PIC in a HeLa-derived cell line. In contrast, nuclear PIC were almost always CA-positive in primary human macrophages, indicating nuclear import of capsids or capsid-like structures. We further show that the CA-targeted inhibitor PF74 exhibits a bimodal mechanism, blocking RTC/PIC association with the host factor CPSF6 and nuclear entry at low, and abrogating reverse transcription at high concentrations. The newly developed system is ideally suited for studying retroviral post-entry events and the roles of host factors including DNA sensors and signaling molecules.

Article and author information

Author details

  1. Ke Peng

    Department of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Walter Muranyi

    Department of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Bärbel Glass

    Department of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Vibor Laketa

    Partner site Heidelberg, German Center for Infection Research, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Stephen R Yant

    Gilead Sciences Inc., Foster City, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Luong Tsai

    Gilead Sciences Inc., Foster City, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Tomas Cihlar

    Gilead Sciences Inc., Foster City, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Barbara Müller

    Department of Infectious Diseases, Virology, University Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Hans-Georg Kräusslich

    Department of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany
    For correspondence
    hans-georg.kraeusslich@med.uni-heidelberg.de
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Wesley I Sundquist, University of Utah, United States

Version history

  1. Received: July 22, 2014
  2. Accepted: December 15, 2014
  3. Accepted Manuscript published: December 17, 2014 (version 1)
  4. Version of Record published: January 15, 2015 (version 2)

Copyright

© 2014, Peng et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,679
    views
  • 614
    downloads
  • 140
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ke Peng
  2. Walter Muranyi
  3. Bärbel Glass
  4. Vibor Laketa
  5. Stephen R Yant
  6. Luong Tsai
  7. Tomas Cihlar
  8. Barbara Müller
  9. Hans-Georg Kräusslich
(2014)
Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid
eLife 3:e04114.
https://doi.org/10.7554/eLife.04114

Share this article

https://doi.org/10.7554/eLife.04114

Further reading

    1. Microbiology and Infectious Disease
    Hina Khan, Partha Paul ... Dibyendu Sarkar
    Research Article

    Survival of Mycobacterium tuberculosis within the host macrophages requires the bacterial virulence regulator PhoP, but the underlying reason remains unknown. 3′,5′-Cyclic adenosine monophosphate (cAMP) is one of the most widely used second messengers, which impacts a wide range of cellular responses in microbial pathogens including M. tuberculosis. Herein, we hypothesized that intra-bacterial cAMP level could be controlled by PhoP since this major regulator plays a key role in bacterial responses against numerous stress conditions. A transcriptomic analysis reveals that PhoP functions as a repressor of cAMP-specific phosphodiesterase (PDE) Rv0805, which hydrolyzes cAMP. In keeping with these results, we find specific recruitment of the regulator within the promoter region of rv0805 PDE, and absence of phoP or ectopic expression of rv0805 independently accounts for elevated PDE synthesis, leading to the depletion of intra-bacterial cAMP level. Thus, genetic manipulation to inactivate PhoP-rv0805-cAMP pathway decreases cAMP level, stress tolerance, and intracellular survival of the bacillus.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Natalia E Ketaren, Fred D Mast ... John D Aitchison
    Research Advance

    To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.